Sensus Healthcare to Host Fourth Quarter 2020 Financial Results and Business Update Conference Call on February 25, 2021
February 18 2021 - 8:00AM
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device
company specializing in highly effective, non-invasive treatments
for both oncological and non-oncological conditions, announces that
management will hold a conference call on Thursday, February 25,
2021 at 4:30 p.m. Eastern time to discuss the financial results for
the fourth quarter of 2020. In addition, management will provide a
business update and a discussion on recent and upcoming milestones.
To access the conference call, the dial-in
numbers are 888-390-3967 (U.S. and Canada Toll Free), 862-298-0702
(International). Please direct the operator to be connected to the
Sensus Healthcare conference call. The call will be webcast live
and can be accessed at the following link, which also may be found
in the Investor Relations section of the Company’s website at
www.sensushealthcare.com.
Following the conclusion of the conference call,
a replay will be available and can be accessed by dialing
888-539-4649 (U.S. and Canada Toll Free), or 754-333-7735
(International). At the system prompt, dial the replay code –
155222 followed by the # sign. Playback will automatically begin.
An archived webcast of the call will also be available in the
Investor Relations section of the Company’s website for a period of
time.
About Sensus Healthcare, Inc.
Sensus Healthcare, Inc. is a medical device
company specializing in highly effective, non-invasive,
minimally-invasive and cost-effective treatments for both
oncological and non-oncological conditions. The Sculptura™
modulated robotic brachytherapy radiation oncology system provides
targeted Directional Anisotropic Radiation Therapy (ART) and
Brachytherapy utilizing our proprietary, state-of-the-art 3D Beam
Sculpting™ to treat patients undergoing cancer treatment during
surgery, or at the tumor site, fast and efficiently. Sensus also
offers its proprietary low-energy X-ray technology known as
superficial radiation therapy (SRT), which is the culmination of
more than a decade of research and development, to treat
non-melanoma skin cancers and keloids with its SRT-100™, SRT-100+™
and SRT-100 Vision™ systems. With its portfolio of innovative
medical device products, Sensus provides revolutionary treatment
options to enhance the quality of life of patients around the
world.
For more information, visit
www.sensushealthcare.com.
Contact: LHA Investor Relations Kim Sutton
Golodetz212-838-3777kgolodetz@lhai.com
# # #
Sensus Healthcare (NASDAQ:SRTS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Sensus Healthcare (NASDAQ:SRTS)
Historical Stock Chart
From Sep 2023 to Sep 2024